Pharmacy Grand Rounds

C[MV] You Later: Letermovir for Prevention of Cytomegalovirus Infection

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Cytomegalovirus (CMV) is an opportunistic infection that occurs frequently in hematopoietic stem cell transplant (HSCT) recipients, causing significant morbidity and mortality. Traditionally, ganciclovir and valganciclovir have been utilized for CMV prophylaxis and treatment; however, their myelosuppressive properties become problematic in patients following HSCT. Letermovir, a new antiviral agent that does not share these myelosuppressive effects, was approved in 2017 for CMV prophylaxis in HSCT recipients. In this presentation, I will review the literature supporting use of letermovir for CMV prophylaxis in HSCT, identify patients who would benefit from a letermovir-based prophylaxis strategy, and discuss investigational uses for this agent.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Explain the difference between pre-emptive and prophylaxis strategies for cytomegalovirus infection prevention
2. Select patients that may benefit from letermovir prophylaxis based on existing literature
3. Identify areas of investigational use of letermovir

Session Announcement

Session Slides

FACULTY INFORMATION

Mikhaila L. Rice, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Mikhaila received a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy in Pittsburgh, PA.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests in hematology, oncology, immunology, and infectious disease.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Mikhaila L. Rice, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Letermovir

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS